Treatment of neurotrophic keratopathy with substance-P-derived peptide (FGLM) and insulin-like growth factor I.
Chikama
T
T
Fukuda
K
K
Morishige
N
N
Nishida
T
T
D003316:Corneal Diseases / Q000188:drug therapy* / Q000209:etiology; D003389:Cranial Nerve Diseases / Q000150:complications; D004359:Drug Therapy, Combination; D019573:Epithelium, Corneal / Q000187:drug effects; D005260:Female; D006801:Humans; D007334:Insulin-Like Growth Factor I / Q000627:therapeutic use*; D008875:Middle Aged; D009842:Oligopeptides / Q000627:therapeutic use*; D010243:Paralysis / Q000150:complications; D014276:Trigeminal Nerve; D014792:Visual Acuity; D014945:Wound Healing / Q000187:drug effects
D009842:Oligopeptides; C112946:phenylalanyl-glycyl-leucyl-methioninamide; D007334:Insulin-Like Growth Factor I